RhumbLine Advisers
RADX

RhumbLine Advisers’s Radiopharm Theranostics RADX Stock Holding History

RhumbLine Advisers’s Portfolio RADX Stock Details RADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$519 Buy
121
+115
+1,917% +$562 ﹤0.01% 4010
2025
Q4 		$31 Buy
+6
New +$32 ﹤0.01% 4113

Other funds holding RADX

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
RP
Regal Partners Sydney, NSW, Australia $1.84B AUM 54.78% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers's RADX Position: Q1 2026 in Review

RhumbLine Advisers increased its Radiopharm Theranostics (RADX) stake by 1,917% in Q1 2026, buying an estimated $562 and bringing the position to 121 shares worth $519. The position accounts for ﹤0.01% of the portfolio, ranked #4010.

RhumbLine Advisers first reported a position in RADX in Q4 2025 and has held it in 2 quarters since. 7 funds tracked by Wall St. Rank hold RADX as of Q1 2026.

  • RhumbLine Advisers held 121 shares of Radiopharm Theranostics worth $519 as of Q1 2026.
  • RhumbLine Advisers bought 115 Radiopharm Theranostics shares in Q1 2026, an estimated $562.
  • Radiopharm Theranostics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #4010 holding.
  • RhumbLine Advisers first reported a position in Radiopharm Theranostics in Q4 2025 and has held it in 2 quarters since.
  • 7 funds tracked by Wall St. Rank held Radiopharm Theranostics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.